Abstract: Objective: To investigate the efficacy of adalimumab in the treatment of plaque psoriasis with or without metabolic syndrome. Methods: The data of patients with plaque psoriasis (with or without metabolic syndrome) from September 2020 to March 2021 were collected. PASI change at 0, 4, 8, 12 weeks and Spearman's correlation of the patients treated with adalimumab were analyzed. Results: A total of 20 patients with psoriasis were treated with adalimumab, of which 1 case was interrupted. Of 19 patients who completed treated, 11 were complicated with  metabolic syndrome. The PASI of 19 patients from 9.7 (2.0, 15.6) to 3.3 (0.4, 4.2). The rate of the patients with metabolic syndrome recovered to PASI 75/PASI 90 were 45% and 0%, that of the patients with no metabolic syndrome were 50% and 50%. There was a negative correlation between efficacy of adamizumab and metabolic syndrome in patients with plaque psoriasis (r=0.679, P<0.01). Conclusion: Adalimumab is effective in the treatment of plaque psoriasis, and metabolic syndrome reduces the effect of adalimumab.

Key words: psoriasis, metabolic syndrome, adalimumab